• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

GEP-NETS 更新:胃-肠-胰神经内分泌肿瘤手术的综述。

GEP-NETS update: a review on surgery of gastro-entero-pancreatic neuroendocrine tumors.

机构信息

Pancreatic Surgery UnitUniversità Politecnica delle Marche, Via Conca, 71, 60126 Ancona, ItalyDepartment of SurgeryUniversity of Verona, Verona, Italy.

Pancreatic Surgery UnitUniversità Politecnica delle Marche, Via Conca, 71, 60126 Ancona, ItalyDepartment of SurgeryUniversity of Verona, Verona, Italy

出版信息

Eur J Endocrinol. 2014 Oct;171(4):R153-62. doi: 10.1530/EJE-14-0173. Epub 2014 Jun 11.

DOI:10.1530/EJE-14-0173
PMID:24920289
Abstract

The incidence of neuroendocrine tumors (NETs) has increased in the last decades. Surgical treatment encompasses a panel of approaches ranging from conservative procedures to extended surgical resection. Tumor size and localization usually represent the main drivers in the choice of the most appropriate surgical resection. In the presence of small (<2 cm) and asymptomatic nonfunctioning NETs, a conservative treatment is usually recommended. For localized NETs measuring above 2 cm, surgical resection represents the cornerstone in the management of these tumors. As they are relatively biologically indolent, an extended resection is often justified also in the presence of advanced NETs. Surgical options for NET liver metastases range from limited resection up to liver transplantation. Surgical choices for metastatic NETs need to consider the extent of disease, the grade of tumor, and the presence of extra-abdominal disease. Any surgical procedures should always be balanced with the benefit of survival or relieving symptoms and patients' comorbidities.

摘要

在过去几十年中,神经内分泌肿瘤 (NETs) 的发病率有所增加。手术治疗包括一系列方法,从保守手术到广泛的切除术。肿瘤大小和定位通常是选择最合适的手术切除方法的主要驱动因素。对于小的(<2cm)且无症状的无功能 NETs,通常建议采用保守治疗。对于大于 2cm 的局限性 NETs,手术切除是这些肿瘤治疗的基石。由于它们的生物学行为相对惰性,即使存在晚期 NETs,广泛切除也常常是合理的。NET 肝转移的手术选择范围从有限的切除到肝移植。转移性 NET 的手术选择需要考虑疾病的范围、肿瘤的分级和是否存在腹腔外疾病。任何手术程序都应始终与生存或缓解症状和患者合并症的获益相平衡。

相似文献

1
GEP-NETS update: a review on surgery of gastro-entero-pancreatic neuroendocrine tumors.GEP-NETS 更新:胃-肠-胰神经内分泌肿瘤手术的综述。
Eur J Endocrinol. 2014 Oct;171(4):R153-62. doi: 10.1530/EJE-14-0173. Epub 2014 Jun 11.
2
Surgical management of neuroendocrine tumors.神经内分泌肿瘤的外科治疗
Best Pract Res Clin Endocrinol Metab. 2016 Jan;30(1):93-102. doi: 10.1016/j.beem.2015.10.003. Epub 2015 Oct 8.
3
Surgery for GEP-NETs.胃肠胰神经内分泌肿瘤的外科治疗。
Best Pract Res Clin Gastroenterol. 2012 Dec;26(6):819-31. doi: 10.1016/j.bpg.2012.12.005.
4
Surgery for gastroenteropancreatic neuroendocrine tumors (GEPNETS).胃肠胰神经内分泌肿瘤(GEPNETs)的外科治疗。
Endocrinol Metab Clin North Am. 2011 Mar;40(1):163-71, ix. doi: 10.1016/j.ecl.2010.12.004.
5
HSP90 expression and early recurrence in gastroenteropancreatic neuroendocrine tumors: Potential for a novel therapeutic target.HSP90 表达与胃肠胰神经内分泌肿瘤的早期复发:潜在的新型治疗靶点。
Surg Oncol. 2020 Dec;35:460-465. doi: 10.1016/j.suronc.2020.09.018. Epub 2020 Oct 7.
6
New and Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors.胃肠胰神经内分泌肿瘤的新型及新兴治疗方案
Clin Adv Hematol Oncol. 2015 May;13(5 Suppl 5):1-18; quiz 1 p following 18.
7
Gastroenteropancreatic neuroendocrine tumors: Role of surgery.胃肠胰神经内分泌肿瘤:手术的作用。
Ann Endocrinol (Paris). 2019 Jun;80(3):175-181. doi: 10.1016/j.ando.2019.04.009. Epub 2019 Apr 11.
8
Resection of primary tumor may prolong survival in metastatic gastroenteropancreatic neuroendocrine tumors.原发肿瘤切除术可能延长转移性胃肠胰神经内分泌肿瘤患者的生存时间。
Surgery. 2019 Mar;165(3):644-651. doi: 10.1016/j.surg.2018.09.006. Epub 2018 Oct 23.
9
Resection of the primary tumor improves survival in patients with gastro-entero-pancreatic neuroendocrine neoplasms with liver metastases: A SEER-based analysis.基于 SEER 的分析:原发肿瘤切除术可改善伴肝转移的胃肠胰神经内分泌肿瘤患者的生存。
Cancer Med. 2019 Sep;8(11):5128-5136. doi: 10.1002/cam4.2431. Epub 2019 Jul 22.
10
Survival prognostic factors of gastro-enteric-pancreatic neuroendocrine tumors after primary tumor resection in a single tertiary center: Comparison of gastro-enteric and pancreatic locations.单中心三级医疗机构中胃肠胰神经内分泌肿瘤原发肿瘤切除术后的生存预后因素:胃肠部位与胰腺部位的比较
Eur J Surg Oncol. 2015 Jun;41(6):751-7. doi: 10.1016/j.ejso.2015.02.011. Epub 2015 Apr 3.

引用本文的文献

1
The clinical benefits of [F]AlF-NOTA-octreotide PET/CT in staging and restaging patients with gastroenteropancreatic neuroendocrine neoplasms: comparison of [F]FDG PET/CT.[F]AlF-NOTA-奥曲肽PET/CT在胃肠胰神经内分泌肿瘤患者分期及再分期中的临床应用:与[F]FDG PET/CT的比较
BMC Med Imaging. 2025 Jul 11;25(1):280. doi: 10.1186/s12880-025-01824-9.
2
eTFC-01: a dual-labeled chelate-bridged tracer for SSTR2-positive tumors.eTFC - 01:一种用于SSTR2阳性肿瘤的双标记螯合桥连示踪剂。
EJNMMI Radiopharm Chem. 2024 May 22;9(1):44. doi: 10.1186/s41181-024-00272-0.
3
Personalized treatment of well-differentiated gastric neuroendocrine tumors based on clinicopathological classification and grading: A multicenter retrospective study.
基于临床病理分类和分级的胃神经内分泌肿瘤的个体化治疗:一项多中心回顾性研究。
Chin Med J (Engl). 2024 Mar 20;137(6):720-728. doi: 10.1097/CM9.0000000000003029. Epub 2024 Feb 22.
4
Defining Tumor Microenvironment as a Possible Target for Effective GEP-NENs Immunotherapy-A Systematic Review.将肿瘤微环境定义为有效的胃肠胰神经内分泌肿瘤免疫治疗的可能靶点——一项系统综述
Cancers (Basel). 2023 Oct 31;15(21):5232. doi: 10.3390/cancers15215232.
5
Safety and efficacy of endoscopic ultrasound-guided radiofrequency ablation for pancreatic neuroendocrine neoplasms: Systematic review and meta-analysis.内镜超声引导下射频消融治疗胰腺神经内分泌肿瘤的安全性和有效性:系统评价与荟萃分析
Dig Endosc. 2024 Apr;36(4):395-405. doi: 10.1111/den.14681. Epub 2023 Oct 11.
6
Efficacy and Safety of Endoscopic Ultrasound-Guided Radiofrequency Ablation for Pancreatic Neuroendocrine Tumors: A Systematic Review and Metanalysis.内镜超声引导下射频消融治疗胰腺神经内分泌肿瘤的疗效和安全性:系统评价和荟萃分析。
Medicina (Kaunas). 2023 Feb 14;59(2):359. doi: 10.3390/medicina59020359.
7
What have we learnt from the past - would treatment decisions for GEP-NET patients differ between 2012 to 2016 by the new recommendations in 2022?我们从过去学到了什么——按照 2022 年的新建议,2012 年至 2016 年间 GEP-NET 患者的治疗决策是否会有所不同?
BMC Cancer. 2023 Feb 13;23(1):148. doi: 10.1186/s12885-023-10567-1.
8
Patterns of Lymph Node Metastasis and Optimal Surgical Strategy in Small (≤20 mm) Gastroenteropancreatic Neuroendocrine Tumors.胃胰神经内分泌肿瘤(≤20mm)的淋巴结转移模式与最佳手术策略。
Front Endocrinol (Lausanne). 2022 Jul 21;13:871830. doi: 10.3389/fendo.2022.871830. eCollection 2022.
9
Health-related quality of life and treatment effects in patients with well-differentiated gastroenteropancreatic neuroendocrine neoplasms: A systematic review and meta-analysis.胃肠胰神经内分泌肿瘤患者的健康相关生活质量和治疗效果:系统评价和荟萃分析。
Eur J Cancer Care (Engl). 2021 Nov;30(6):e13504. doi: 10.1111/ecc.13504. Epub 2021 Aug 30.
10
Long-term outcome after resection and thermal hepatic ablation of pancreatic neuroendocrine tumour liver metastases.切除和热消融治疗胰腺神经内分泌肿瘤肝转移的长期疗效。
BJS Open. 2021 Jul 6;5(4). doi: 10.1093/bjsopen/zrab062.